ClinicalTrials.gg
CompletedNCT01022853Updated Jul 30, 2018Results posted

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

A Phase 1 interventional study of BI 6727 and BIBF 1120 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-30.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid tumours.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 30 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed diagnosis of advanced, non resectable and/or solid tumours, who have failed conventional treatment, and for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
  2. Age > or = 18 years
  3. European Cooperative Oncology Group performance status \< or = 2
  4. Written in accordance with International Conference on Harmonization -Good Clinical Practice (ICH-GCP) and local legislation
  5. Recovery from grade 2-4 therapy-related toxicities from previous systemic anti-cancer therapies or radiotherapy (except alopecia)

Exclusion criteria

Exclusion criteria:

  1. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the trial
  2. Known to the trial drugs or their
  3. Treatment with any other drug or participation in any other interventional trial within 28 days before first administration of trial drug (BIBF 1120) or concomitantly with this trial
  4. Systemic anti-cancer therapy or radiotherapy within 28 days before start of therapy or concomitantly with this trial. The restriction does not apply to and bisphosphonates
  5. Active infectious disease infection or I/II
  6. Other currently requiring another anti-cancer therapy
  7. Clinical evidence of symptomatic progressive brain or during the past 6 months
  8. Known inherited predisposition to bleeding or thrombosis
  9. Radiographic evidence of cavitary or necrotic tumours
  10. History of haemoptysis within the past 3 months
  11. Centrally located tumours with radiographic evidence (Computed Tomography or Magnetic Resonance Imaging) of local invasion of major blood vessels
  12. (ANC) less than 1.5 x 1000000000/L
  13. Count (PLT) less than 100 x 1000000000/L
  14. Total > (ULN)
  15. Alaninaminotransferase () and/or Aspartateaminotransferase (AST) >= 1.5 x ULN (in case of liver : ALT and AST >= 2.5 x ULN)
  16. Serum creatinine > 1.5 mg/dl
  17. Major injuries and/or surgery or bone fracture within 28 days before first administration of trial drug (BIBF 1120), or planned surgical procedures during the trial period
  18. Known history of clinically relevant (e.g. long QT syndrome)
  19. History of severe haemorrhagic or thromboembolic event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis)
  20. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid \< or = 325mg per day)
  21. Active alcohol or drug abuse
  22. Women and men who are sexually active and unwilling to use a medically acceptable method of during the trial
  23. Pregnancy or breast-feeding
  24. Patients unable to comply with the protocol
  25. Uncontrolled hypertension
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    BIBF 1120 and BI 6727

    Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120

    Drug: BI 6727 · Drug: BIBF 1120

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).

    DLT was defined as: 1. Drug-related CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia

    Time frame: 28 days

  2. Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib

    The MTD was determined using a 3+3 design with de-escalation. The MTD was defined as the highest dose level at which maximal 1 out of 6 patients experienced DLT in the first course of the escalation nd de-escalation phase. However, all DLT's occurring in the trial were considered for selection of the recommended dose for further development.

    Time frame: 28 days

Secondary outcomes

  1. Number of Participants With Drug Related Adverse Events

    Number of participants with investigator-defined drug related adverse events.

    Time frame: From first study drug administration until 28 days after the last administration of any study medication, up to 485 days

  2. Number of Participants With Dose Limiting Toxicities

    Number of participants with dose limiting toxicities (DLTs). DLT was defined as: 1. Drug-related CTCAE grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia

    Time frame: From first study drug administration until 28 days after the last administration of any study medication, up to 485 days

  3. Cmax of Volasertib

    Maximum measured concentration (Cmax) in plasma of Volasertib in Cycle 1.

    Time frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion

  4. CL of Volasertib

    Total plasma Clearance (CL) of Volasertib in Cycle 1.

    Time frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion

  5. Vss of Volasertib

    Volume of distribution at steady state (Vss) of Volasertib in Cycle 1.

    Time frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion

  6. Cmax of Nintedanib

    Maximum measured concentration (Cmax) of Nintedanib in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.

    Time frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9

  7. AUC(0-6h) of Nintedanib

    Area under the concentration-time curve (AUC) of Nintedanib over the time interval 0 to 6 hours in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.

    Time frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9

  8. Tmax of Nintedanib

    Time from dosing to the maximum measured concentration, Cmax, of Nintedanib (tmax) in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.

    Time frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9

  9. Number of Patients With Best Overall Response

    Best overall response based on response evaluation criteria in solid tumors (RECIST) version 1.1. Best overall response is defined as the best overall response (complete response, partial response, stable disease, progressive disease or not evaluable) since the start of treatment.

    Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

  10. Number of Patients With Objective Response (OR)

    Objective tumor response based on response evaluation criteria in solid tumors (RECIST) version 1.1. OR is defined as complete response (CR) or partial response (PR) as best response throughout the study.

    Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

  11. Number of Patients With Disease Control

    Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Disease control is defined as complete response (CR), partial response (PR) or stable disease (SD) as best response throughout the study.

    Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

  12. Duration of Disease Control

    Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Patients who had a best overall tumour response of complete response (CR), partial response (PR) or stable disease (SD) were assessed to show disease control.

    Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

  13. Progression Free Survival (PFS)

    PFS is defined as the time from start of treatment with study medication to tumour progression or death whichever occurs first. Tumour response was to be documented using appropriate techniques such as magnetic resonance imaging (MRI) or computer tomography (CT).

    Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

07

Results

Posted Jul 30, 2018

Participant flow

An uncontrolled, open-label, dose escalation study in cohorts of patients following the '3+3 design with de-escalation'. After entering the study, cohorts of patients were sequentially allocated to the dose levels.

Participant flow — Overall Study
Milestone100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Started341382
Completed00000
Not completed341382
Withdrew: Progressive disease231171
Withdrew: Dose-limiting toxicity00001
Withdrew: Withdrawal by subject01110
Withdrew: Other not stated above10100

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).

DLT was defined as: 1. Drug-related CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia

Time frame:
28 days
Reported as:
Number · participants
Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).
participants100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).00322
SecondaryNumber of Participants With Drug Related Adverse Events

Number of participants with investigator-defined drug related adverse events.

Time frame:
From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
Reported as:
Number · participants
Number of Participants With Drug Related Adverse Events
participants100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Number of Participants With Drug Related Adverse Events331272
SecondaryNumber of Participants With Dose Limiting Toxicities

Number of participants with dose limiting toxicities (DLTs). DLT was defined as: 1. Drug-related CTCAE grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia

Time frame:
From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
Reported as:
Number · participants
Number of Participants With Dose Limiting Toxicities
participants100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Number of Participants With Dose Limiting Toxicities01622
SecondaryCmax of Volasertib

Maximum measured concentration (Cmax) in plasma of Volasertib in Cycle 1.

Time frame:
0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
Reported as:
Geometric mean · ng/mL
Cmax of Volasertib
ng/mL100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Cmax of Volasertib164 ± 77.6409 ± 23.3532 ± 33.3534 ± 25.51210 ± 54.1
SecondaryCL of Volasertib

Total plasma Clearance (CL) of Volasertib in Cycle 1.

Time frame:
0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
Reported as:
Geometric mean · mL/min
CL of Volasertib
mL/min100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
CL of Volasertib720 ± 19.30685 ± 4.22792 ± 34.2849 ± 29.3589 ± 18.3
SecondaryVss of Volasertib

Volume of distribution at steady state (Vss) of Volasertib in Cycle 1.

Time frame:
0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
Reported as:
Geometric mean · L
Vss of Volasertib
L100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Vss of Volasertib5710 ± 39.95590 ± 6.535010 ± 34.76080 ± 21.22710 ± 87.3
SecondaryCmax of Nintedanib

Maximum measured concentration (Cmax) of Nintedanib in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.

Time frame:
5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
Reported as:
Geometric mean · ng/mL
Cmax of Nintedanib
ng/mL100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib
Cmax of Nintedanib22.5 ± 58.030.2 ± 66.236.7 ± 53.334.2 ± 53.8
SecondaryAUC(0-6h) of Nintedanib

Area under the concentration-time curve (AUC) of Nintedanib over the time interval 0 to 6 hours in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.

Time frame:
5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
Reported as:
Geometric mean · ng*h/mL
AUC(0-6h) of Nintedanib
ng*h/mL100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib
AUC(0-6h) of Nintedanib69.5 ± 29.9104.0 ± 59.4135.0 ± 48.8121.0 ± 51.0
SecondaryTmax of Nintedanib

Time from dosing to the maximum measured concentration, Cmax, of Nintedanib (tmax) in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.

Time frame:
5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
Reported as:
Median · h
Tmax of Nintedanib
h100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib
Tmax of Nintedanib3.00 (3.00 to 3.00)1.88 (1.00 to 2.75)2.42 (1.00 to 3.00)2.00 (1.00 to 6.00)
SecondaryNumber of Patients With Best Overall Response

Best overall response based on response evaluation criteria in solid tumors (RECIST) version 1.1. Best overall response is defined as the best overall response (complete response, partial response, stable disease, progressive disease or not evaluable) since the start of treatment.

Time frame:
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Reported as:
Number · participants
Number of Patients With Best Overall Response
participants100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Complete Response00100
Partial Response00100
Stable Disease22741
Progressive Disease12330
Not Evaluable00000
Missing00111
SecondaryNumber of Patients With Objective Response (OR)

Objective tumor response based on response evaluation criteria in solid tumors (RECIST) version 1.1. OR is defined as complete response (CR) or partial response (PR) as best response throughout the study.

Time frame:
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Reported as:
Number · participants
Number of Patients With Objective Response (OR)
participants100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Objective Response (OR)00200
Missing00111
PrimaryMaximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib

The MTD was determined using a 3+3 design with de-escalation. The MTD was defined as the highest dose level at which maximal 1 out of 6 patients experienced DLT in the first course of the escalation nd de-escalation phase. However, all DLT's occurring in the trial were considered for selection of the recommended dose for further development.

Time frame:
28 days
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib
mgVolasertib in Combination With Nintedanib
Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib300
SecondaryNumber of Patients With Disease Control

Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Disease control is defined as complete response (CR), partial response (PR) or stable disease (SD) as best response throughout the study.

Time frame:
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Reported as:
Number · participants
Number of Patients With Disease Control
participants100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Number of Patients With Disease Control22941
SecondaryDuration of Disease Control

Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Patients who had a best overall tumour response of complete response (CR), partial response (PR) or stable disease (SD) were assessed to show disease control.

Time frame:
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Reported as:
Median · days
Duration of Disease Control
days100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg NintedanibTotal Patients
Duration of Disease Control163.0 (114.0 to 212.0)348.0 (184.0 to 512.0)141.0 (74.0 to 447.0)215.0 (94.0 to 394.0)56.0 (56.0 to 56.0)161.5 (56.0 to 512.0)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from start of treatment with study medication to tumour progression or death whichever occurs first. Tumour response was to be documented using appropriate techniques such as magnetic resonance imaging (MRI) or computer tomography (CT).

Time frame:
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Reported as:
Median · days
Progression Free Survival (PFS)
days100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg NintedanibTotal Patients
Progression Free Survival (PFS)114.0 (45.0 to 212.0)116.0 (35.0 to 512.0)99.0 (30.0 to 447.0)72.5 (8.0 to 394.0)83.0 (56.0 to 110.0)96.5 (8.0 to 512.0)

Adverse events

Collected over All adverse events (AEs) that occurred during therapy with the study medication, or within 28 days after the last administration of any study medication, up to 485 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100 mg Volasertib + 200 mg Nintedanib—0/3 (0%)3/3 (100%)
200 mg Volasertib + 200 mg Nintedanib—0/4 (0%)4/4 (100%)
300 mg Volasertib + 200 mg Nintedanib—5/13 (38.5%)13/13 (100%)
350 mg Volasertib + 200 mg Nintedanib—2/8 (25%)8/8 (100%)
400 mg Volasertib + 200 mg Nintedanib—1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
Event100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
Febrile neutropeniaBlood and lymphatic system disorders0/30/40/130/81/2
NeutropeniaBlood and lymphatic system disorders0/30/40/130/81/2
ThrombocytopeniaBlood and lymphatic system disorders0/30/40/130/81/2
Intestinal obstructionGastrointestinal disorders0/30/40/131/80/2
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/40/131/80/2
PyrexiaGeneral disorders0/30/41/130/80/2
Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/41/130/80/2
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/41/130/80/2
Bladder obstructionRenal and urinary disorders0/30/41/130/80/2
HaematuriaRenal and urinary disorders0/30/41/130/80/2
Most frequent other events
Showing 10 of 100
Most frequent other events
Event100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg Nintedanib
AnaemiaBlood and lymphatic system disorders0/30/44/132/82/2
LeukopeniaBlood and lymphatic system disorders0/30/44/131/82/2
NauseaGastrointestinal disorders3/32/44/136/81/2
VomitingGastrointestinal disorders1/32/46/133/82/2
AstheniaGeneral disorders2/32/48/135/82/2
Chest painGeneral disorders3/31/41/130/80/2
Abdominal pain upperGastrointestinal disorders1/33/41/132/81/2
NeutropeniaBlood and lymphatic system disorders0/31/49/134/81/2
DiarrhoeaGastrointestinal disorders2/31/48/134/81/2
ThrombocytopeniaBlood and lymphatic system disorders0/31/48/135/81/2

Baseline characteristics

Treated Set - All patients who received ≥1 dose of study medication were included in the treated set.

Age, Continuous
Age, Continuous(years)100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg NintedanibTotal
Mean53.0 ± 9.260.0 ± 7.157.5 ± 8.853.1 ± 12.959.0 ± 5.756.3 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)100 mg Volasertib + 200 mg Nintedanib200 mg Volasertib + 200 mg Nintedanib300 mg Volasertib + 200 mg Nintedanib350 mg Volasertib + 200 mg Nintedanib400 mg Volasertib + 200 mg NintedanibTotal
Female1172112
Male2366118
08

Study locations

2 sites
  • 1230.7.39002 Boehringer Ingelheim Investigational Site
    Ancona, Italy
  • 1230.7.39001 Boehringer Ingelheim Investigational Site
    Milano, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2009
First posted
Dec 1, 2009
Start
Dec 2009
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Jul 30, 2018
Last update
Jul 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01022853
Responsible party
Sponsor
First posted
Dec 1, 2009
Start date
Dec 2009
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Jul 30, 2018
Last update
Jul 30, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BI 6727 · Nintedanib

Start the discussion